Food & Drug Administration (2024) National Association of Boards of Pharmacy FDAs concerns with unapproved GLP-1 drugs used for weight loss, U.S
The beyond-use date indicated on the Tirzepatide ODT packaging represents the date beyond which the medication should not be used, as established by stability testing under specified storage conditions
In Phase 3 TRIUMPH-1 data, diarrhea was reported in 25.2% to 34.1% of participants taking retatrutide, constipation in 23.8% to 26.1%, and vomiting in 10.6% to 25.3%, compared with lower rates among participants receiving placebo
For the best results, its recommended to combine the medication with a balanced diet and regular physical activity
What Prescribers Should Verify Before Authorizing Compounded Semaglutide Before you write a prescription for compounded semaglutide, due diligence is non-negotiable